Mutations in BRCA1 and PALB2 genes were significantly associated with the high risk of ovarian cancer G1, while CHEK2 missense mutation (c.470T>C) was associated with 2-times elevated risk of BOT. This evidence concerns the gene PALB2 and ovarian carcinoma.